https://orcid.org/0000-0002-4786-3642
References
- Arribas Castro I, Maluquer C, Pomares H, et al. B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature. Leukemia & lymphoma.
- geyer mb, shaffer bc, bhatnagar b, et al. Lenalidomide-associated b-cell all: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. blood adv. 2023;7(13):3087–3098. doi:10.1182/bloodadvances.2022009212
- Barnell EK, Skidmore ZL, Newcomer KF, et al. Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma. Blood Adv. 2023;7(2):236–245. doi:10.1182/bloodadvances.2022007496
- Parrondo RD, Rahman ZA, Heckman MG, et al. Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. Blood Cancer J. 2022;12(6):87. doi:10.1038/s41408-022-00680-y
- Liu J, Huang B, Gu J, et al. Clinical characteristics and prognosis of secondary acute lymphoblastic leukemia in patients with multiple myeloma during Long-Term thalidomide maintenance. J Pers Med. 2023;13(3):412. doi:10.3390/jpm13030412
- Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–1791. doi:10.1056/NEJMoa1114138
- Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320. doi:10.1056/NEJMoa1611750
- Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132–147. doi:10.1056/NEJMoa2204925
- McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous Stem-Cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279–3289. doi:10.1200/JCO.2017.72.6679
- Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15(3):333–342. doi:10.1016/S1470-2045(13)70609-0
- Saleem K, Franz J, Klem ML, et al. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol. 2022;9(12):e906–e918. doi:10.1016/S2352-3026(22)00289-7
- Ragon BK, Shah MV, D'Souza A, et al. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023;7(12):2746–2757. doi:10.1182/bloodadvances.2022009138
- Jones JR, Cairns DA, Gregory WM, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the myeloma XI trial. Blood Cancer J. 2016;6(12):e506–e506. doi:10.1038/bcj.2016.114
- Pawlyn C, Menzies T, Davies FE, et al. Defining the optimal duration of lenalidomide maintenance after autologous stem cell transplant – data from the myeloma XI trial. Blood. 2022;140(Supplement 1):1371–1372. doi:10.1182/blood-2022-165376
- San-Miguel J, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139(4):492–501. doi:10.1182/blood.2020010439
- Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(25):2901–2912. doi:10.1200/JCO.21.01935
- Korde N, Diamond B, Burge M, et al. Maintenance therapy cessation for sustained MRD negative multiple myeloma patients. Blood. 2022;140(Supplement 1):2397–2398. doi:10.1182/blood-2022-169937
- Derman BA, Major A, Major S, et al. Prospective trial using multimodal measurable residual disease negativity to guide discontinuation of maintenance therapy in multiple myeloma (MRD2STOP). Blood. 2022;140(Supplement 1):2108–2109. doi:10.1182/blood-2022-158643
- Noori S, Wijnands C, Langerhorst P, et al. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J. 2023;13(1):30. doi:10.1038/s41408-023-00803-z
- Sperling AS, Guerra VA, Kennedy JA, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022;140(16):1753–1763. doi:10.1182/blood.2021014956
- Wudhikarn K, Padrnos L, Lasho T, et al. Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. Am J Hematol. 2021;96(5):E157–E162.